Deep brain stimulation (DBS) currently comprises only about a quarter of the worldwide neuromodulation device market, but growth in this segment is strong. Both large and small competitors have targeted DBS, which has the potential to address a number of highly prevalent and underserved diseases and disorders.

The cardiac interventional suite has historically welcomed high-tech, cutting-edge tools. But with hospitals scrutinizing expenditures more closely than ever before, such tools must now prove themselves. Hospitals are now placing a premium on technologies that can improve safety, efficiency, and flexibility while streamlining workflow. A handful of companies are now offering products designed to meet these needs, and providers are starting to take notice.

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.